(E)-2-(hydroxyimino)-3,4-dihydronaphthalen-1(2H)-one | 39262-02-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (E)-2-(hydroxyimino)-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: (2E)-2-hydroxyimino-3,4-dihydronaphthalen-1-one
• CAS: 39262-02-7
• 化学式: C₁₀H₉NO₂
• 分子量: 175.187
• InChiKey: CMBOOGVJHNRHQC-PKNBQFBNSA-N

物化性质

• 熔点：
  164 °C (decomp)
• 沸点：
  360.9±35.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-2-(hydroxyimino)-3,4-dihydronaphthalen-1(2H)-one 、 盐酸 生成 2-氨基-3,4-二氢-1(2H)-萘酮盐酸盐(1:1)
  参考文献：
  名称：

  REIFENRATH W. G.; FRIES D. S., J. MED. CHEM., 1979, 22, NO 2, 204-206

  摘要：

  DOI：
• 作为产物：
  描述：

  1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 在 亚硝酸特丁酯 作用下， 以 水 为溶剂， 以88 %的产率得到(E)-2-(hydroxyimino)-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  β-酮酸与亚硝酸叔丁酯的水介导脱羧自由基亚硝化：获得α-肟基酮

  摘要：

  开发了一种实用的 β-酮酸与亚硝酸叔丁酯在水中的无催化剂脱羧自由基亚硝化反应。涉及激进分子的策略在相对温和的条件下运作良好。该协议为构建具有不同电子和空间特性的各种芳香族和脂肪族α-肟基酮提供了一种有效的途径，产率从良好到优异（高达 95%）。

  DOI：

  10.1039/d2nj04175h

文献信息

• Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20030149022A1

  公开（公告）日：2003-08-07

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及一种抑制β-淀粉样肽释放和/或其合成的化合物，因此在治疗阿尔茨海默病方面具有实用性。本发明还涉及包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。
• 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES
  申请人：Fukunaga Kenji

  公开号：US20090233918A1

  公开（公告）日：2009-09-17

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R 2 represents a hydrogen or the like; R 3 represents methyl group or the like; R 20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R 4 represents hydrogen or the like; R 5 represents hydrogen or the like; R 6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH 2 , oxygen atom, NH, or the like; any one or more of R 5 and R 6 , R 5 and R 4 , R 6 and R 4 , X and R 5 , X and R 4 , X and R 6 , and R 6 and R 6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I），其手性异构体或药物可接受的盐：其中，R2代表氢或类似物；R3代表甲基基团或类似物；R20代表卤素原子或类似物；q表示0到3的整数；Z代表氮原子，CH或类似物；R4代表氢或类似物；R5代表氢或类似物；R6代表取代的烷氧基或类似物；p表示0到3的整数；X代表键，CH2，氧原子，NH或类似物；R5和R6，R5和R4，R6和R4，X和R5，X和R4，X和R6以及R6和R6中的任何一个或多个可以结合形成环，用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，例如神经退行性疾病（例如阿尔茨海默病）。
• TETRACYCLIC INHIBITORS OF JANUS KINASES
  申请人：Rodgers James D.

  公开号：US20090215766A1

  公开（公告）日：2009-08-27

  The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

  本发明提供了一种可以调节Janus激酶活性的化合物，这些化合物可用于治疗与Janus激酶活性相关的疾病，例如免疫相关疾病和癌症。
• Hexahydronaphth(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical formulation containing them
  申请人：Merck & Co., Inc.

  公开号：EP0080115A2

  公开（公告）日：1983-06-01

  Hexahydronaphth[1,2-b]-1,4-oxazines have dopaminergic activity and display α2-adrenergic receptor antagonism. They are useful in the treatment of parkinsonism, depression and hypertension. An important method of preparation is by ring closure of the appropriate 2-chloroacetamido- tetrahydronaphthalen-1-ol and reduction of the resulting cyclic amide carbonyl group.

  六氢萘并[1,2-b]-1,4-噁嗪具有多巴胺能活性，并显示出α2-肾上腺素能受体拮抗作用。 它们可用于治疗帕金森病、抑郁症和高血压。 一种重要的制备方法是将适当的 2-氯乙酰胺基四氢萘-1-醇闭环，并还原由此产生的环状酰胺羰基。
• 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2423207A2

  公开（公告）日：2012-02-29

  A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH2, oxygen atom, NH, or the like; any one or more of R5 and R6, R5 and R4, R6 and R4, X and R5, X and R4, X and R6, and R3 and R6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  式 (I) 所代表的化合物、其光学活性异构体或其药用盐： 其中 R2 代表氢或类似物；R3 代表甲基或类似物；R20 代表卤原子或类似物；q 代表 0 至 3 的整数；Z 代表氮原子、CH 或类似物；R4 代表氢或类似物；R5 代表氢或类似物；R6 代表取代的烷氧基或类似物；p 代表 0 至 3 的整数；X代表键、CH2、氧原子、NH或类似物；R5和R6、R5和R4、R6和R4、X和R5、X和R4、X和R6、R3和R6中的任意一个或多个可相互结合形成环，用于预防和/或治疗由tau蛋白激酶1亢进引起的疾病，如神经退行性疾病（如阿尔茨海默病）。如阿尔茨海默病）。